Rki 677 ⟶

The RKI 677 has several potential benefits, including:

However, there are also challenges associated with the RKI 677: rki 677

The phase 2a trial evaluated the vaccine's efficacy and safety in a larger cohort of participants. The results demonstrated that the vaccine had a significant efficacy in preventing COVID-19, with a vaccine efficacy of 67.2% against severe COVID-19. The RKI 677 has several potential benefits, including: